HCC vs. CERE, CNX, ARCH, HNRG, CEIX, METC, AREC, OVV, PR, and PAA
Should you be buying Warrior Met Coal stock or one of its competitors? The main competitors of Warrior Met Coal include Cerevel Therapeutics (CERE), CNX Resources (CNX), Arch Resources (ARCH), Hallador Energy (HNRG), CONSOL Energy (CEIX), Ramaco Resources (METC), American Resources (AREC), Ovintiv (OVV), Permian Resources (PR), and Plains All American Pipeline (PAA).
Warrior Met Coal (NYSE:HCC) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap oils/energy companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
Warrior Met Coal received 194 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 62.66% of users gave Warrior Met Coal an outperform vote.
Warrior Met Coal has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
Warrior Met Coal has a net margin of 25.94% compared to Cerevel Therapeutics' net margin of 0.00%. Warrior Met Coal's return on equity of 24.71% beat Cerevel Therapeutics' return on equity.
92.3% of Warrior Met Coal shares are owned by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are owned by institutional investors. 1.0% of Warrior Met Coal shares are owned by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Warrior Met Coal presently has a consensus price target of $72.80, suggesting a potential upside of 9.72%. Cerevel Therapeutics has a consensus price target of $42.67, suggesting a potential upside of 4.07%. Given Warrior Met Coal's stronger consensus rating and higher possible upside, research analysts clearly believe Warrior Met Coal is more favorable than Cerevel Therapeutics.
In the previous week, Cerevel Therapeutics had 1 more articles in the media than Warrior Met Coal. MarketBeat recorded 5 mentions for Cerevel Therapeutics and 4 mentions for Warrior Met Coal. Cerevel Therapeutics' average media sentiment score of 1.19 beat Warrior Met Coal's score of 0.69 indicating that Cerevel Therapeutics is being referred to more favorably in the news media.
Warrior Met Coal has higher revenue and earnings than Cerevel Therapeutics.
Summary
Warrior Met Coal beats Cerevel Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Warrior Met Coal News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Warrior Met Coal Competitors List
Related Companies and Tools
